Other languages Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Real-time Estimate Cboe BZX Other stock markets 08:11:02 29/04/2024 pm IST			5-day change	1st Jan Change
14.28 ^USD	+4.31%		+10.71%	-34.15%

25/04	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained	MT
25/04	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14/02
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC	25/01
Sage Therapeutics, Inc. Announces Changes to Board of Directors	08/01
Biogen, Sage Therapeutics Say Oral Pill Zurzuvae for Postpartum Depression Now Available by Prescription in US	14/12
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE 50 mg (Two 25 mg Capsules Per Day) CIV	14/12
Sage Therapeutics Q3 Loss Widens; Revenue Rises	08/11
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900	07/11
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Sage Therapeutics Says US FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease	18/23/18
Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease	18/23/18
Sage Therapeutics to Lay Off 40% Staff Amid Efforts to Support Financial Position	31/23/31
Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%	31/23/31
Sage Therapeutics to cut 40% of jobs after depression drug setback	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Other languages

Filters